What are the side effects of Toripalimab?

In the Toripalimab (Toripalimab) combination study, the most common adverse reactions (≥20%) were nausea, vomiting, decreased appetite, constipation, hypothyroidism, rash, fever, diarrhea, peripheral neuropathy, and cough , musculoskeletal pain, upper respiratory tract infection, insomnia, dizziness, and malaise; the most common grade 3 or 4 laboratory abnormalities (≥2%) were neutropenia, lymphopenia, decreased hemoglobin, thrombocytopenia, decreased potassium, decreased sodium, increased alanine aminotransferase, increased or decreased magnesium, decreased calcium, increased aspartate aminotransferase, and increased bilirubin.

In studies of toripalimab monotherapy, the most common (≥20%) adverse reactions were fatigue, hypothyroidism, and musculoskeletal pain; the most common grade 3 or 4 laboratory abnormalities (≥2%) were decreased sodium, lymphopenia, decreased hemoglobin, decreased fibrinogen, increased lipase, increased amylase, decreased phosphate, increased aspartate aminotransferase, increased glucose, and increased triglycerides. ToripalimabThere are also warnings and precautions regarding immune-mediated adverse reactions, infusion-related reactions, complications and fetal harm in patients receiving allogeneic hematopoietic stem cell transplantation (HSCT).

In the trial , patients were assigned to receive 0.3 mg/kg, 1 mg/kg, 3 mg/kg, 10 mg/kg, or 240 mg toripalimab by intravenous infusion every 2 weeks; 33.3% of patients in the 0.3 mg/kg group, 1 Anti-drug antibodies were detected in 42.9% of patients in the mg/kg group and in 16.7% of patients in the 3 mg/kg group, but not in the 10 mg/kg or 240 mg groups. These results indicate the low immunogenicity of toripalimab in vivo.